Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 per cent reduction in the combined relative risk versus placebo of...
Source: newswire.ca